GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioNTech SE (WBO:BNTX) » Definitions » NonCurrent Deferred Liabilities

BioNTech SE (WBO:BNTX) NonCurrent Deferred Liabilities : €438 Mil (As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is BioNTech SE NonCurrent Deferred Liabilities?

Non-Current Deferred Liabilities represents the non-current portion of obligations, which is a liability that usually would have been paid but is now pas due.

BioNTech SE's non-current deferred liabilities for the quarter that ended in Dec. 2023 was €438 Mil.

BioNTech SE NonCurrent Deferred Liabilities Historical Data

The historical data trend for BioNTech SE's NonCurrent Deferred Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioNTech SE NonCurrent Deferred Liabilities Chart

BioNTech SE Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
NonCurrent Deferred Liabilities
Get a 7-Day Free Trial 97.11 72.10 75.70 54.60 438.20

BioNTech SE Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
NonCurrent Deferred Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 54.60 50.90 306.60 311.10 438.20

BioNTech SE NonCurrent Deferred Liabilities Related Terms

Thank you for viewing the detailed overview of BioNTech SE's NonCurrent Deferred Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


BioNTech SE (WBO:BNTX) Business Description

Industry
Address
An der Goldgrube 12, Mainz, RP, DEU, D-55131
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and small-molecule immunomodulators. BioNTech is partnered with several large pharmaceutical companies, including Roche, Eli Lilly, Pfizer, Sanofi, and Genmab. COVID-19 vaccine Comirnaty is its first commercialized product.

BioNTech SE (WBO:BNTX) Headlines

From GuruFocus